Arcellx initiated with a Buy at Redburn Atlantic

Redburn Atlantic initiated coverage of Arcellx with a Buy rating and $109 price target “Arcellx is a clinical-stage biotechnology company focused on the development of CAR-T cell therapy for the treatment of blood cancers, the analyst tells investors in a research note. The firm says the company’s “unique” technology platform, known as D-Domain, is differentiated from other CAR-T cell therapy platforms and has been validated by its lead asset with best-in-class potential. Redburn believes the early-stage ARC-SparX can offer a potential solution with a more tailored and safer approach to CAR-T cell therapy in the future.